key: cord-0827980-vdklc2ig authors: Fuzo, Carlos A.; Martins, Ronaldo B.; Fraga-Silva, Thais F.C.; Amstalden, Martin K.; De Leo, Thais Canassa; Souza, Juliano P.; Lima, Thais M.; Faccioli, Lucia H.; França, Suzelei C.; Bonato, Vania L.D.; Arruda, Eurico; Dias-Baruffi, Marcelo title: Drug repurposing to face Covid-19: Celastrol, a potential leading drug capable of inhibiting SARS-CoV-2 replication and induced inflammation date: 2021-04-20 journal: bioRxiv DOI: 10.1101/2021.04.20.439992 sha: 4964cd58d998995791bfee47455730277cebaac7 doc_id: 827980 cord_uid: vdklc2ig The global emergence of Covid-19 has caused huge human casualties. Clinical manifestations of the disease vary from asymptomatic to lethal, and the symptomatic form can be associated with cytokine storm and non-homeostatic inflammatory response. In face of the urgent demand for effective drugs to treat Covid-19, we have searched for candidate compounds using a drug repurposing approach based on in silico analysis followed by biological validation. Here we identified celastrol, a pentacyclic triterpene isolated from Tripterygium wilfordii Hook F – a plant used in traditional Chinese medicine – as one of the best compounds out of 39 repurposed drug candidates. Celastrol reverted gene expression signature from SARS-CoV-2-infected cells; bound with high-affinity energy to viral molecular targets such as main protease (Mpro) and receptor-biding domain (RBD); inhibited SARS-CoV-2 replication in monkey (Vero and Vero-ACE2) and human (Caco-2 and Calu-3) cell lines; and decreased interleukin-6 (IL-6) secretion in SARS-CoV-2-infected human cell lines. Interestingly, celastrol acted in a concentration-dependent manner, with undetectable signs of cytotoxicity. Therefore, celastrol is a promising lead drug candidate to treat Covid-19 due to its ability to suppress SARS-CoV-2 replication and IL-6 production in infected cells, two critical events in the pathophysiology of this disease. Covid-19 (Coronavirus Disease 2019), caused by the β-coronavirus SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2), was first reported to the World Health Organization in January 2020 after a local pneumonia outbreak of unknown etiology in Wuhan, China 1,2 . SARS-CoV-2 has been rapidly and effectively transmitted from human-to-human and became a worldwide pandemic that affected more than 137 million people in April 2021 3, 4 . The devastating effects of Covid-19 on global public health and economy have demanded urgent efforts to discover potential drug and vaccine candidates to prevent and treat this disease. Many immunization strategies have been studied since the beginning of the pandemic, demonstrating the fast and extraordinary achievement of pharmaceutical companies in the development of vaccines for Covid-19. Although there are 289 vaccine candidates under development, from which 20 were under phase 3 clinical trial in February 2021 [5] [6] [7] , there are many challenges to achieve an efficient global immunization, such as production limitations, efficacy levels, restrictions on use, dosing procedures, storage requirements, price, emergence of SARS-CoV-2 mutants, and promotion of durable immunological memory [7] [8] [9] [10] [11] [12] . Despite the availability of effective vaccines, the quick discovery of drugs to prevent and treat SARS-CoV-2 infection is a critical demand to face Covid-19 13 . The drug reuse strategy accelerates the discovery of candidate compounds with known activities associated with reducing the SARS-CoV-2 viral load or promoting a better clinical evolution of Covid-19 14, 15 . One aspect of the immunopathology of this disease that stands out is non-hemostatic inflammation associated with cytokine storm involving by several mediators, including interleukin-6 (IL-6), which is a severity biomarker of this illness [16] [17] [18] . In this sense, bioinformatics and computational biology are powerful and multidimensional in silico tools for drug discovery and repurposing of compounds approved or under clinical trial [19] [20] [21] [22] . Some of the currently employed strategies to find drugs applicable in Covid-19 have focused on (i) host or virus targets, such as the receptor-binding domain (RBD) present in spike glycoprotein and angiotensin-converting enzyme II (ACE2), which mediate virus-host cell interaction 23, 24 ; (ii) proteins/enzymes from virus biosynthesis machinery, such as main protease (M pro ) and RNA-dependent RNA polymerase (RdRp) [25] [26] [27] ; and (iii) reversion of the host gene expression signature of SARS-CoV-2-infected cells 15, 28, 29 . This study used in silico predictions to repurpose drug candidates that could concomitantly reverse the SARS-CoV-2 gene expression induced in host cells, including IL-6, and target proteins/enzymes essential to the SARS-CoV-2 life cycle, followed by biological validation of the best candidate drug repurposed. Bscore was the sum of DEG weighting factors and it was normalized by the sum of all weighting factors. The graphical representation of drug signatures data and scores were generated with pheatmap 36 and ggplot2 packages 37 in R software 38 . The compounds capable of reversing SARS-CoV-2 infection signature (selected in Section 2.1) were submitted to molecular docking on three SARS-CoV-2 protein targets: the catalytic site of M pro , the RNA binding site of RdRp, and the RBD domain of spike glycoprotein, using multiple structural conformations. Here we used ensemble docking to increase the sampling and avoid unique conformational bias. We have previously generated the representative structures for RBD (unpublished results) using ten centroid clusters obtained from a 600 ns trajectory, with the aid of molecular dynamics simulation based on the deposited cocrystal RDB/ACE2 structure (PDB id 6M0J) 39 . The multiple structures of M pro and RdRp were obtained from Protein Data Bank (PDB) 40 (Table S1 ). The heteroatoms were removed from M pro and RdRp structures, the resulting structures were repaired, and the energy was minimized with FoldX 41 . AutoDockTools 42 was used to prepare drug and protein input structures for docking analysis and grid box definitions (Table S1 ). Docking analysis was carried out using Autodock Vina 43 with exhaustiveness parameter equal to 20. Graphical representations of energy results were plotted with ggplot2 R package and molecular model structures were drawn with Pymol 44 and Discovery Studio Visualizer ® (version-2020) 45 . In silico analysis guided the selection of a candidate drug for biological validation, considering the drug's ability to reverse the genetic signature of SARS-CoV-2 infection and its binding affinities to molecular viral targets. Briefly, the ten best repurposed drugs were selected based on Qscore values. A compound with high predicted median binding affinity energy for RBD, M Pro , and RdRpand thereby with strong potential to inhibit the functions of these molecular targetswas selected using molecular docking data. Photomicrographs were taken using the Olympus ix51 inverted microscope and analyzed using the QCapture Pro 6.0 software under 200× magnification (QImaging) 49 , in order to examine whether celastrol interfered with SARS-CoV-2 cytopathic effects in Vero CCL-81 cells. The supernatants were collected for RNA extraction and viral load was quantified using a standard curve. All the infections were conducted in technical triplicate. Cytotoxicity of celastrol (Sigma-Aldrich) to Vero CCL-81, Vero CCL-81-ACE2, Calu-3, and Caco-2 was determined using the Alamar Blue Cell Viability protocol (Thermo Scientific, Waltham, USA), according to the manufacturer's instructions. Briefly, the cells were seeded into a 96-well plate to grow as monolayers and treated with celastrol (250 or 1000 nM) in DMSO (0.05%) or DMSO (5%, v/v; cell death reference) for 24 hours. Alamar Blue reagent (10% v/v) was added to the cells, and the plate was incubated at 37 °C, for 4 hours. Median fluorescence intensity was measured using the SpectraMax i-3 (Molecular Devices) microplate reader, with excitation and emission wavelengths set at 530 and 590 nm, respectively. The mean value from the control (untreated cells) was set as 100%, and the viability of cells from each treatment condition was calculated relative to this value, in triplicate. The SARS-CoV-2 genome was quantified using primer-probe sets for N2 and RNAse-P housekeeping gene, following USA-CDC protocols (Table 1) To quantify the amount of virus produced, a tenfold serial dilution of the plasmid was prepared in the range from 10 6 to 1 plasmid copy. The coefficient of determination (R 2 ) for the plasmid standard curve was 0.999, with efficiency above 91% reached using any set of primers/probe 51 . IL-6 levels were quantified in Caco-2 and Calu-3 cell culture supernatants using the Human DuoSet ELISA assay kit (R&D Systems, USA), according to the manufacturer's instructions. The IL-6 detection limit was 9.38-1200 pg.mL -1 . Raw data for viral load from RT-PCR was transformed into log scale, normalized, and analyzed by non-linear regression using dose-response curve fitting and the equation log (inhibitor) versus normalized response with variable slope. All the experimental data are expressed as mean ± standard error of the mean (SEM), and they were plotted and analyzed using GraphPad Prism 7 software 52 . Statistical significance was analyzed by one-way analysis of variance (ANOVA) followed by Tukey's post-test for multiple comparisons. Differences were considered significant at P < 0.05. The P values were labeled as * P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. We determined the genetic signature of SARS-CoV-2-infected NHBE cells based on transcriptome data reported in the literature 30 . Then, we used |log2(FC)| > 1 and padj < 0.05 as selection criteria, and identified 64 up-and 8 down-regulated DEGs in infected NHBE cells (Table S2 ). The over-representation analysis of selected DEGs in Reactome pathways annotations indicated the existence of 22 significantly enriched biological pathways (Fig. 1a , Table S3 ). The top enriched pathways were related to interleukin, chemokine, and interferon signaling, according to literature data 30 , and were closely related to biological pathways involved in SARS-CoV-2 human infection [53] [54] [55] [56] . Considering that the genetic signature described here was composed of DEGs associated with Covid-19 pathophysiology, we searched for candidate drugs that could reverse the genetic signature of NHBE-infected cells using the L1000CDS2 protocol to define the Qscore. Table S4 ). Based on the Qscore values from these 50 drug signatures, a medium value score was defined as 0.26 (Fig. 1c) . CGP-60474, a cyclin-dependent kinase inhibitor 57 , exhibited the best- (Fig.1c) . In the set of best-ranked drugs by Qscore, CGP-60474, celastrol, and A443654 also presented Bscore values higher than the mean score of 0.49 (Fig. 1d) , suggesting that they are potential reversers of biological pathways related to SARS-CoV-2 infection. We have searched for candidate drugs with two potential actions: to revert the genetic signature of iii) RNA-binding cleft of RdRp (Fig. 2a) . We determined the pose with the highest binding affinity energy (ΔGbind in kcal.mol -1 ) for each ensemble's structures of all selected compounds and viral molecular targets (Fig. 2b) . The ΔGbind values ranged from -9.6 kcal.mol -1 for the leucine-rich repeat kinase inhibitor XMD-1150 61 binding to M pro to -4.5 kcal.mol -1 for the histone deacetylase inhibitor vorinostat 62 binding to RBD2. The ensemble dockings on different conformations led to energetic variations but not to wide dispersion of ΔGbind values, demonstrating that certain drugs maintained their high binding affinity to different conformations of the studied targets. Celastrol exhibited the most attractive ΔGbind median values of energy out of the first ten best-ranked drugs for the viral targets (M pro = -7.3, RDB1= -6.2, and RBD2 =-6.7 kcal.mol -1 ), and presented the second most attractive ΔGbind median value for RdRp (-7.8 kcal.mol -1 - Fig. 2b) . The chemical pattern of celastroltarget interactions was composed of conventional hydrogen bonds, carbon-hydrogen bonds, Pi interactions, and van der Waals interactions that favored a more attractive binding affinity of celastrol to M pro , RBD1, and RBD2 with ΔGbind equal to -8.7, -6.8, and -8.1 kcal.mol -1 , respectively (Fig. 3) . The celastrol binding to M pro catalytic site was mediated by the sigma Pi interaction among the E-ring O2, His41 and hydrogen bound in Thr25, and OH group of A-ring C3. The mean atomic distance between the B-ring C6 and the Cys145 sulfur atoma critical amino acid of the M pro catalytic sitewas 0.63 nm (range: 0.43-1.33 nm) (Fig. 3) , suggesting an appropriate geometry to the formation of a covalent bond. In addition, celastrol exhibited one of the highest Bscore values (0.53) among the 39 drugs analyzed, indicating that this compound had a great potential to revert the genetic signature of SARS-CoV-2 infection (Fig. 1d ). Of note, the protein kinase inhibitor WZ-4-145 63 displayed the best ΔGbind (-8.3 kcal.mol -1 ) to RdRp due to a myriad combination of interactions, including conventional hydrogen bonds, alkyl, and Pi interactions ( Fig. 2b and Fig. 3 ). Some drugs with high affinity to the studied targets, such as XMD-1150 to M pro and KIN001-265 to RBD1, RBD2, and RdRp, were poorly ranked in reverse signature repurposing but they could be relevant due to their predicted binding abilities. The ΔGbind, QScore, and Bscore values of celastrol supported its selection to biological validation. In silico analysis indicated that celastrol is a potential drug candidate to treat Covid-19 due to its ability To examine whether cytotoxicity mediated the anti-viral effect of celastrol, we determined the cell viability of the four cell lines treated with celastrol at two concentrations, 250 nM and 1000 nM, which promoted its minimal and maximum anti-viral action in human cell lines, respectively. Celastrol-treated cells and the negative control had similar viability levels, of nearly 100% (Fig. 5a-d) . Treatment with 5% DMSO (positive control) decreased cell viability by more than 80%. Celastrol also significantly reduced SARS-CoV-2 cytopathic effect in a concentration-dependent manner (Fig. S1 ). as IL-6, as demonstrated by in silico analysis, and celastrol reversed this effect (Fig. 1) . To test this prediction, we determined IL-6 levels in the supernatant of SARS-CoV-2-infected cells treated or not with celastrol. This compound at 500 and 1000 nM significantly decreased IL-6 production by Caco-2-infected cells, and at 1000 nM it decreased IL-6 production by Calu-3-infected cells (Fig.6) . Curiously, Caco-2-infected cells produced around ten-fold lower IL-6 levels than Calu-3-infected cells. This phenomenon may be associated with the lower viral load in culture supernatants of Caco-2 cells, as compared with samples from Calu-3 cells (Fig. 4c ,d). Here, we identified 39 potential repurposed drug candidates for Covid-19 treatment based on in silico prediction of their abilities to revert the genetic signature of SARS-CoV-2-infected cells and bind with high affinity to viral targets. One of the in silico best-ranked candidates was celastrol, which was also able to inhibit Considering that the direct interaction between celastrol and viral targets can mediate its antiviral activity 79, 80 , we demonstrated its ability to bind M pro , RBD1, RDB2, and RdRp, which are essential to the viral life cycle 19, [24] [25] [26] [27] . A previous study has described the celastrol interaction with the catalytic site of the SARS-CoV M pro 81 . Docking simulations on the catalytic site of M pro revealed that the celastrol binding energy was higher than that of most compounds tested here. Our models suggested that the high binding affinity of celastrol to M pro involved the sigma Pi interaction between the E-ring O2 and His41, associated with the hydrogen bond between Thr25 and the hydroxyl group of A-ring C3, in agreement with literature reports 79, 80 . In addition, our atomic distance analysis suggested that B-ring C6 interacted with Cys145a critical amino acid of M pro catalytic siteby forming a Michael's adduct; this inhibition mechanism of celastrol was also Our findings demonstrated that celastrol was able to reduce both SARS-CoV-2 viral load and IL-6 production in two human cell lines, suggesting that this compound exerts anti-SARS-CoV-2 effects of clinical relevance to face the current pandemic. Several pharmacological applications of celastrol are associated with Covid-19 severity, including comorbidities such as obesity, diabetes, hypertension, and metabolic syndrome [95] [96] [97] [98] , and pathological events such as non-homeostatic production of pro-inflammatory cytokines, thrombus generation, and formation of neutrophil extracellular traps [99] [100] [101] . Celastrol is currently under clinical trials to treat a variety of diseases, including different types of cancer, neurodegenerative disorders, and inflammatory conditions such as rheumatoid arthritis, psoriasis, and Crohn's disease [102] [103] [104] [105] [106] . Despite its potential therapeutic effects, there are still some limitations to the use of celastrol, such as its low solubility that results in poor bioavailability, in vitro and in vivo toxicity, and adverse effects that remain to be evaluated 107, 108 . Celastrol was not cytotoxic to all cell lines tested herein, even at the highest concentration (1000 nM), corroborating other reports using Caco-2 cells 109 . At 1000 nM, this compound reduced the SARS-CoV-2-cytopathic effect on Vero CCL-81 cells. A recent study using a mouse model of acute toxicity has demonstrated that celastrol is safe even when orally administered at a high dose (62.5 mg/kg body weight) 110 . Intraperitoneal administration of celastrol (0.25 mg/kg body weight) increases the gamma irradiated-mice survival rate by around 70 78 . To surpass celastrol toxicity, solubility, and pharmacokinetic issues, several pharmaceutical approaches have been proposed, such as nanoencapsulation, liposomes, and sugar-silica nanoparticles [111] [112] [113] . Celastrol has been considered a lead drug for several human illnesses, but its toxicity to humans remains to be determined 64, 73, 114 . To the best of our knowledge, the present study is the pioneer to use the combination between bioinformatic tools and biological approaches to demonstrate that celastrol inhibits the SARS-CoV-2 replication in non-human and human cell lines, and down-regulates IL-6 secretion from infected-human cell lines, reinforcing that celastrol is a potential repurposed drug to treat Covid-19. We are thankful to the Brazilian National Council for Scientific and Technological Development The authors declare no competing interests. DMSO solution (0.05%; vehicle) was used as negative control. Cells were infected using MOI = 1.0 for 2 hours and then treated with celastrol for 48 hours. The detection levels of SARS-CoV-2 RNA were performed in the supernatants of cultures and expressed in viral load using a standard curve described in the Material and Methods section. Statistical differences between celastrol treatments and the negative control were analyzed by ANOVA followed by Tukey's post-test. The significance levels were indicated as * P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. DMSO solutions at 0.05% and 5.0% were used as the negative and positive controls of cell death, respectively. Statistical analysis was performed using ANOVA followed by the Tukey's post-test to compare treatment with celastrol and 5.0% DMSO. ****P < 0.0001. Figure 6 . Celastrol inhibits IL-6 production in SARS-CoV-2-infected human cell lines. ELISA quantification of IL-6 in the culture supernatants from the human cell lines (a) Caco-2 and (b) Calu-3, infected with SARS-CoV-2 (MOI = 1.0) for 2 hours and then treated with celastrol for 48 hours. DMSO solution at 0.05% (vehicle) was used as the negative control. Statistical differences between celastrol treatment and control were analyzed by ANOVA followed by Tukey's post-test. The significance levels were indicated as **P < 0.01, ***P < 0.001, and ****P < 0.0001. The results are expressed as mean ± standard error of the mean (SEM) of IL-6 (pg/mL) and are representative of two independent experiments with Caco-2 cells and one experiment with Calu-3 cells. Table Table 1 . Primers/probe sequences for detection of SARS-CoV-2 genome and housekeeping gene 50 Primer Sequence A Novel Coronavirus from Patients with Pneumonia in China An interactive web-based dashboard to track COVID-19 in real time Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity Global, regional, and national estimates of target population sizes for covid-19 vaccination: descriptive study SARS-CoV-2 variants and ending the COVID-19 pandemic Emergence of a Highly Fit SARS-CoV-2 Variant COVID-19 vaccines: modes of immune activation and future challenges A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2 Lessons from the COVID-19 pandemic for advancing computational drug repurposing strategies The trinity of COVID-19: immunity, inflammation and intervention Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 Combating Devastating COVID -19 by Drug Repurposing A review of network-based approaches to drug repositioning Computational and experimental advances in drug repositioning for accelerated therapeutic stratification A SARS-CoV-2 protein interaction map reveals targets for drug repurposing Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay Structure of Mpro from COVID-19 virus and discovery of its inhibitors Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals Causal network models of SARS-CoV-2 expression and aging to identify candidates for drug repurposing Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles L1000CDS2: LINCS L1000 characteristic direction signatures search engine The reactome pathway knowledgebase He Q-Y. clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters. Omi A Implementation of heatmaps that offers more control over dimensions and appearance Elegant Graphics for Data Analysis R: A Language and Environment for Statistical Computing Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor The Protein Data Bank The FoldX web server: an online force field AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading Isolation, Sequence, Infectivity, and Replication Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS12 Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2 SARS-CoV-2 Inactivation by Ozonated Water: A Preliminary Alternative for Environmental Disinfection An inflammatory cytokine signature predicts COVID-19 severity and survival Temporal and spatial heterogeneity of host response to SARS-CoV-2 pulmonary infection Two distinct immunopathological profiles in autopsy lungs of COVID-19 Novel and Efficient Access to Phenylamino-pyrimidine Type Protein Kinase C Inhibitors Utilizing a Negishi Cross-Coupling Strategy Molecular targets of celastrol derived from Thunder of God Vine: Potential role in the treatment of inflammatory disorders and cancer Potent and selective inhibitors of Akt kinases slow the progress of tumors